journal article·2025-09-24

Neutrophil-Mediated Delivery Platforms for Synergistic Chemo-Immunotherapy of Non-Small-Cell Lung Cancer Therapy

Rongze Sun, Yunshuang Jiao, Jicong Chen, Xiang Pang, Beilin Xue, Jiaqi Yao, Guanpeng Li, Yue Zhang, Jie Yang, Lesheng Teng

Nano Letters· Volume 25· Issue 38
Publisher page

Abstract

Traditional nanocarriers possess good therapeutic efficacy in the treatment of non-small-cell lung cancer (NSCLC), but usually suffer from high immunogenicity, poor biosafety, and low targeting. In this work, a neutrophil-mediated delivery platform constructed from neutrophils (NEs) and paclitaxel/transforming growth factor-β (TGF-β) siRNA loaded cationic liposome, namely, siTGFβ-PLP-NEs, is fabricated for the combination therapy of NSCLC via synergistic chemo-immunotherapy. siTGFβ-PLP-NEs can be targeted to the tumor site and effectively release paclitaxel and siTGFβ, which is conducive to simultaneously inhibiting the proliferation of tumor cells and the expression of TGF-β. The experimental results demonstrate that siTGFβ-PLP-NEs can prevent the transition of tumor-associated NEs from an anti-tumor (N1) phenotype to a pro-tumor (N2) phenotype, enhance CD8 + T cell infiltration, and reduce regulatory T cell (Treg) infiltration, which provides a great promising combination therapy option to use neutrophil-mediated systems as a general-purpose delivery platform for the treatment of NSCLC.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Life Sciences, Jilin University, 2699 Qianjin Street, Changchun 130012, P. R. China

Funding

Department of Science and Technology of Jilin Province · Ministry of Science and Technology of the People's Republic of China

References (53)

Show source-provided references
1. 10.1056/NEJMoa191662310.1056/NEJMoa1916623 ↗
2. 10.1016/S0140-6736(21)00312-310.1016/S0140-6736(21)00312-3 ↗
3. 10.7150/thno.8068710.7150/thno.80687 ↗
4. 10.1038/s41591-021-01450-210.1038/s41591-021-01450-2 ↗
5. 10.1016/j.jtho.2019.01.00610.1016/j.jtho.2019.01.006 ↗
6. 10.1002/smll.20210769010.1002/smll.202107690 ↗
7. 10.7150/ijbs.7095810.7150/ijbs.70958 ↗
8. 10.1186/s13045-020-00881-710.1186/s13045-020-00881-7 ↗
9. 10.1200/JCO.2008.17.716210.1200/JCO.2008.17.7162 ↗
10. 10.1021/acs.nanolett.0c0227210.1021/acs.nanolett.0c02272 ↗
11. 10.1016/j.pharmthera.2014.11.00110.1016/j.pharmthera.2014.11.001 ↗
12. 10.1186/s13578-017-0168-010.1186/s13578-017-0168-0 ↗
13. 10.1016/j.pharmthera.2017.11.00410.1016/j.pharmthera.2017.11.004 ↗
14. 10.1186/s12951-024-02883-w10.1186/s12951-024-02883-w ↗
15. 10.1038/s41392-020-00449-410.1038/s41392-020-00449-4 ↗
16. 10.1021/acs.nanolett.3c0207510.1021/acs.nanolett.3c02075 ↗
17. 10.1186/s13045-021-01187-y10.1186/s13045-021-01187-y ↗
18. 10.1016/j.jconrel.2023.08.02010.1016/j.jconrel.2023.08.020 ↗
19. 10.1038/nature1440710.1038/nature14407 ↗
20. 10.1038/s41467-023-37872-410.1038/s41467-023-37872-4 ↗
21. 10.1038/s41571-019-0222-410.1038/s41571-019-0222-4 ↗
22. 10.1016/j.apsb.2022.08.01210.1016/j.apsb.2022.08.012 ↗
23. 10.1016/j.bbcan.2022.18876210.1016/j.bbcan.2022.188762 ↗
24. 10.1038/s41467-023-37515-810.1038/s41467-023-37515-8 ↗
25. 10.1038/s41568-021-00413-610.1038/s41568-021-00413-6 ↗
26. 10.1038/s41467-022-31141-610.1038/s41467-022-31141-6 ↗
27. 10.1021/acsnano.9b0971310.1021/acsnano.9b09713 ↗
28. 10.1016/j.cell.2023.02.03210.1016/j.cell.2023.02.032 ↗
29. 10.1038/d41586-020-01672-310.1038/d41586-020-01672-3 ↗
30. 10.3389/fimmu.2021.70877010.3389/fimmu.2021.708770 ↗
31. 10.1002/advs.20210524010.1002/advs.202105240 ↗
32. 10.1016/j.ccr.2005.10.01210.1016/j.ccr.2005.10.012 ↗
33. 10.1016/j.immuni.2006.07.01110.1016/j.immuni.2006.07.011 ↗
34. 10.1038/ni154910.1038/ni1549 ↗
35. 10.1038/nature0875010.1038/nature08750 ↗
36. 10.1186/s12943-022-01569-x10.1186/s12943-022-01569-x ↗
37. 10.1007/s12307-014-0147-510.1007/s12307-014-0147-5 ↗
38. 10.1158/1078-0432.CCR-16-204710.1158/1078-0432.CCR-16-2047 ↗
39. 10.1016/j.intimp.2010.11.02110.1016/j.intimp.2010.11.021 ↗
40. 10.1038/s41598-018-30417-610.1038/s41598-018-30417-6 ↗
41. 10.1016/j.ijrobp.2021.07.84510.1016/j.ijrobp.2021.07.845 ↗
42. 10.1111/imr.1317610.1111/imr.13176 ↗
43. 10.1016/j.jconrel.2024.09.03710.1016/j.jconrel.2024.09.037 ↗
44. 10.1111/j.1470-8744.1990.tb00099.x10.1111/j.1470-8744.1990.tb00099.x ↗
45. 10.1016/j.apsb.2022.02.02310.1016/j.apsb.2022.02.023 ↗
46. 10.1016/j.xcrm.2025.10220510.1016/j.xcrm.2025.102205 ↗
47. 10.1038/s41571-024-00959-y10.1038/s41571-024-00959-y ↗
48. 10.1016/j.apmt.2024.10225910.1016/j.apmt.2024.102259 ↗
49. 10.1016/j.celrep.2022.11112810.1016/j.celrep.2022.111128 ↗
50. 10.1016/j.lfs.2023.12202110.1016/j.lfs.2023.122021 ↗
51. 10.1016/j.ccell.2023.03.00810.1016/j.ccell.2023.03.008 ↗
52. 10.1182/blood-2018-11-84454810.1182/blood-2018-11-844548 ↗
53. 10.1016/j.immuni.2020.03.00110.1016/j.immuni.2020.03.001 ↗